IL6 and chronic kidney disease: Ziltivekimab, an IL-6 ligand-inhibiting antibody, showed promising reductions in pro-inflammatory and prothrombotic biomarkers in CKD patients with residual inflammation during the RESCUE (IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk) trial [51].